Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 12/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | GCK | P35557 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 4/20 | 0.39 |
| ▸ | PRNP | P04156 | 1/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL799087 | 0.92 | PIK3CG (0.51) | PIK3CGMEN1KMT2AGCKLMNA | |
| SCHEMBL798939 | 0.91 | PIK3CG (0.50) | PIK3CGMEN1KMT2AGCKLMNA | |
| SCHEMBL798644 | 0.87 | PIK3CG (0.66) | PIK3CGMEN1KMT2AMAPTGCK | |
| SCHEMBL171976 | 0.85 | PIK3CG (0.49) | PIK3CGALDH1A1GCKPIK3CD | |
| SCHEMBL799272 | 0.85 | PIK3CG (0.51) | PIK3CGKDM4EGCKLMNA | |
| SCHEMBL799081 | 0.85 | PIK3CG (0.51) | PIK3CGMEN1KMT2AGCKLMNA | |
| SCHEMBL799350 | 0.84 | GCK (0.47) | PIK3CGMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL799354 | 0.83 | GCK (0.49) | PIK3CGMEN1KMT2AKDM4EL3MBTL1 | |
| SCHEMBL805099 | 0.82 | PIK3CG (0.47) | PIK3CGMEN1KMT2ALMNAPIK3CD | |
| SCHEMBL172045 | 0.82 | PIK3CG (0.54) | PIK3CGMEN1KMT2AALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120071475-A1 | UREA DERIVATIVES HAVING PI3K-INHIBITING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2012-03-22 | — | — | US | disclosed |
| US-20120071475-A1 | UREA DERIVATIVES HAVING PI3K-INHIBITING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2012-03-22 | — | — | US | disclosed |
| EP-2426135-A1 | UREA DERIVATIVE HAVING PI3K INHIBITORY ACTIVITY | Shionogi&Co., Ltd. (JP) | 2012-03-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071475-A1 | UREA DERIVATIVES HAVING PI3K-INHIBITING ACTIVITY | MTOR, STAT3, SLC14A1 | PIK3CG 16/4885MEN1 2694/4885KMT2A 2921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.